* Greg Dane has been appointed chief executive of Neocrin Co., an Irvine biomedical company. He also retains the title of president. Michael Henos, formerly chief executive, will remain chairman of the board of directors of this company, which is still in its development stage. Before joining Neocrin in June, Dane was general manager of Baxter Healthcare Corp.'s Brussels-based global business initiative to develop and commercialize immunotherapies for treating allergic asthma. Before that, he was general manager of Baxter R & D Europe. Neocrin also announced that it has converted from a California general partnership to a Delaware corporation.